Tygacil (tigecycline)
- Region
- 🇪🇺 EU
- Active substance
- tigecycline
- Company
- Pfizer Europe MA EEIG
- Status
- Authorised
- Therapeutic area
- Bacterial Infections; Skin Diseases, Bacterial; Soft Tissue Infections
- EU approval
- Mon 24 Apr 2006
- Application
- EMEA/H/C/000644
- ATC
- J01AA12
- Official record
- www.ema.europa.eu
Indication
Tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections Complicated intra-abdominal infections (cIAI) Tygacil should be used only in situations where other alternative antibiotics are not suitable. Consideration should be given to official guidance on the appropriate use of antibacterial agents. appropriate use of antibacterial agents.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Tigecycline Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Tigecycline Accord Application withdrawn · Accord Healthcare Ltd
Follow Tygacil
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.